Scarica l'app Stockscreener
12.40
1.12%
-0.14
Dopo l'orario di chiusura:
12.30
-0.10
-0.81%
Precedente Chiudi:
$12.54
Aprire:
$12.44
Volume 24 ore:
1.02M
Relative Volume:
0.71
Capitalizzazione di mercato:
$736.36M
Reddito:
$122.29M
Utile/perdita netta:
$122.31M
Rapporto P/E:
5.757
EPS:
2.1539
Flusso di cassa netto:
$12.00M
1 W Prestazione:
+7.22%
1M Prestazione:
+17.87%
6M Prestazione:
+38.86%
1 anno Prestazione:
+38.86%
Intervallo 1D:
$12.20
$12.65
Intervallo di 1 settimana:
$11.39
$12.65
Portata 52W:
$7.16
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(888) 958-1253
Indirizzo
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
12.40 | 706.07M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | BTIG Research | Buy |
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Why (ZVRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Zevra Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium - Quiver Quantitative
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Barchart.com
A rare-disease drug has up to 8 years of real-world data. Zevra will present the findings. - Stock Titan
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Zevra employees receive stock options that vest over four years - Stock Titan
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - marketscreener.com
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
ZVRA Q2 2026 Earnings: EPS Beats Estimates by 27.85% as Bottom-Line Strength ContinuesLow Estimate Range - vinanet.vn
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
FY2026 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: A Biotech Stock with 113% Potential Upside - DirectorsTalk Interviews
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review? - Yahoo Finance
ZVRA Maintained by Citizens -- Price Target Raised to $28.00 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Investors to Connect - ACCESS Newswire
Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings - MarketBeat
Zevra Therapeutics (ZVRA) gains FMR LLC and Abigail Johnson 8.3% stake disclosure - Stock Titan
Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.11, Implies 138% Upside - TradingView
Zevra Therapeutics Q2 Earnings Call Highlights - MarketBeat
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights - GuruFocus
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... - Yahoo Finance
ZVRA Looks 54.4% Undervalued on GF Value™ at $10.54 - GuruFocus
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):